Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Merck
MRK
Merck
(Hold) No pipeline Homerun to replace keytruda. But aggressively acquiring.
AS
AscendedInvestor
Invested
Community Contributor
Published
20 Jul 25
Updated
20 Jul 25
1
Set Fair Value
0
votes
Share
AscendedInvestor
's Fair Value
US$63.00
26.8% overvalued
intrinsic discount
20 Jul
US$79.86
Loading
1Y
-28.9%
7D
-5.0%
Author's Valuation
US$63.0
26.8% overvalued
intrinsic discount
AscendedInvestor's Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AscendedInvestor
's
Fair Value
US$63.0
26.8% overvalued
intrinsic discount
Future estimation in
5 Years
time period
Past
Future
0
64b
2014
2017
2020
2023
2025
2026
2029
2030
Revenue US$54.9b
Earnings US$13.7b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
3.11%
Pharma revenue growth rate
1.14%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.40%
Calculation
US$13.72b
Earnings '30
x
15.00x
PE Ratio '30
=
US$205.84b
Market Cap '30
US$205.84b
Market Cap '30
/
2.40b
No. shares '30
=
US$85.93
Share Price '30
US$85.93
Share Price '30
Discounted to 2025 @ 6.40% p.a.
=
US$63.00
Fair Value '25
